Enzolytics Comments on Recent Market Activity and Shareholder Update
DALLAS, TX / ACCESSWIRE / February 6, 2020 / Enzolytics- (OTC Pink Sheet-ENZC) was notified by FINRA that an unauthorized press release titled, “Enzolytics Inc., Launches Coronavirus Prevention Kit” was distributed to the public. Enzolytics and its management had no knowledge of this press release in any manner, and disavows any information contained in this press release. The company does not have a “Coronavirus Prevention Kit” and finds the claim reckless and fraudulent.
Enzolytics, Inc., Inc. is diligently working to bring its filings current and continue with its initiatives for the commercialization of its proprietary proteins for the treatment of HIV.
Enzolytics flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. ITV-1 has also been shown to have anti-viral efficacy. Enzolytics continues to work with its Bulgarian partner, Immunotech Laboratories, BG, to complete the validation of the production process to submit the final documents to the Bulgarian drug agency in order to obtain registration.
Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of HIV/AIDS. Enzolytics is committed to creating drugs for the better health of mankind
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world.
While Enzolytics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Enzolytics to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests.
Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Enzolytics or any other person that the objectives and plans of Enzolytics will be achieved should not regard the forward-looking statements as a representation.
Phone: (972) 292-9414
SOURCE: Enzolytics, Inc.
View source version on accesswire.com: